148 related articles for article (PubMed ID: 22449226)
1. A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Nonomura A
Pathol Int; 2012 Apr; 62(4):226-31. PubMed ID: 22449226
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.
Rena O; Boldorini LR; Gaudino E; Casadio C
J Surg Oncol; 2011 Nov; 104(6):701-5. PubMed ID: 21437912
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Inatsugi N; Nonomura A
J Clin Pathol; 2012 Jun; 65(6):522-7. PubMed ID: 22412050
[TBL] [Abstract][Full Text] [Related]
4. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Kadota E; Nonomura A
Pathol Int; 2010 May; 60(5):395-9. PubMed ID: 20518890
[TBL] [Abstract][Full Text] [Related]
5. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
6. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma.
Davidson B; Reich R; Lazarovici P; Flørenes VA; Risberg B; Nielsen S; Sert B; Bedrossian C
Lung Cancer; 2004 May; 44(2):159-65. PubMed ID: 15084380
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
Monaco SE; Shuai Y; Bansal M; Krasinskas AM; Dacic S
Am J Clin Pathol; 2011 Apr; 135(4):619-27. PubMed ID: 21411785
[TBL] [Abstract][Full Text] [Related]
8. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
9. EGFR expression and gene copy number in triple-negative breast carcinoma.
Gumuskaya B; Alper M; Hucumenoglu S; Altundag K; Uner A; Guler G
Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
[TBL] [Abstract][Full Text] [Related]
10. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
Gaafar R; Bahnassy A; Abdelsalam I; Kamel MM; Helal A; Abdel-Hamid A; Eldin NA; Mokhtar N
Lung Cancer; 2010 Oct; 70(1):43-50. PubMed ID: 20347505
[TBL] [Abstract][Full Text] [Related]
11. Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features.
El-Zammar OA; Zhang S; Katzenstein AL
Diagn Mol Pathol; 2009 Sep; 18(3):133-7. PubMed ID: 19704257
[TBL] [Abstract][Full Text] [Related]
12. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
Watzka SB; Setinek U; Huber M; Cantonati H; Lax F; Watson S; Weigel G; Müller MR
Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):107-10. PubMed ID: 18048409
[TBL] [Abstract][Full Text] [Related]
13. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
Kobayashi M; Takeuchi T; Ohtsuki Y
Anticancer Res; 2008; 28(1A):197-208. PubMed ID: 18383846
[TBL] [Abstract][Full Text] [Related]
14. Podoplanin as a marker for mesothelioma.
Kimura N; Kimura I
Pathol Int; 2005 Feb; 55(2):83-6. PubMed ID: 15693854
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast.
Shao MM; Zhang F; Meng G; Wang XX; Xu H; Yu XW; Chen LY; Tse GM
Histopathology; 2011 Aug; 59(2):264-73. PubMed ID: 21884205
[TBL] [Abstract][Full Text] [Related]
16. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
Frey AB; Wali A; Pass H; Lonardo F
Histopathology; 2007 May; 50(6):720-6. PubMed ID: 17493236
[TBL] [Abstract][Full Text] [Related]
18. Comparison of genomic abnormality in malignant mesothelioma by the site of origin.
Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Nakai T; Iizuka N; Maruyama H; Ohbayashi C
J Clin Pathol; 2014 Dec; 67(12):1038-43. PubMed ID: 25217709
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]